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Abstract
Infants born to HIV-infected mothers are at high risk of becoming infected during gestation or the breastfeeding period. A
search is thus warranted for vaccine formulations that will prevent mother-to-child HIV transmission. The LAMP/gag DNA
chimeric vaccine encodes the HIV-1 p55gag fused to the lysosome-associated membrane protein-1 (LAMP-1) and has been
shown to enhance anti-Gag antibody (Ab) and cellular immune responses in adult and neonatal mice; such a vaccine
represents a new concept in antigen presentation. In this study, we evaluated the effect of LAMP/gag DNA immunization on
neonates either before conception or during pregnancy. LAMP/gag immunization of BALB/c mice before conception by the
intradermal route led to the transfer of anti-Gag IgG1 Ab through the placenta and via breastfeeding. Furthermore, there
were an increased percentage of CD4+CD25+Foxp3+T cells in the spleens of neonates. When offspring were immunized
with LAMP/gag DNA, the anti-Gag Ab response and the Gag-specific IFN-c-secreting cells were decreased. Inhibition of anti-
Gag Ab production and cellular responses were not observed six months after immunization, indicating that maternal
immunization did not interfere with the long-lasting memory response in offspring. Injection of purified IgG in conjunction
with LAMP/gag DNA immunization decreased humoral and cytotoxic T-cell responses. LAMP/gag DNA immunization by
intradermal injection prior to conception promoted the transfer of Ab, leading to a diminished response to Gag without
interfering with the development of anti-Gag T- and B-cell memory. Finally, we assessed responses after one intravenous
injection of LAMP/gag DNA during the last five days of pregnancy. The intravenous injection led to in utero immunization. In
conclusion, DNA vaccine enconding LAMP-1 with Gag and other HIV-1 antigens should be considered in the development
of a protective vaccine for the maternal/fetal and newborn periods.
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Introduction
Despite the use of antiretroviral regimens to prevent intrapartum
and breast milk HIV transmission [1], mother-to-child transmission
(MTCT) of HIV-1 is still the major route of pediatric infection [2].
Effective implementation of drug regimens for long-term prophylaxis is
jeopardized by several factors, such as infant toxicity and an inadequate
health care infrastructure in some of the most affected countries.
Vertical transmission of HIV-1 depends on the maternal HIV-1
viral load, infant exposure to infected fluids upon delivery and
breastfeeding, and the duration and regimen of antiretroviral
treatment [3,4]. Yet, even in the absence of treatment, 55 to 80%
of infants exposed to HIV-1 remain uninfected [5].
Children who escape MTCT are again at risk of infection when
they become sexually active adolescents. Vaccines that are
administered to HIV-1-infected women during the neonatal
period or pregnancy and that are able to induce high levels of
neutralizing Ab with long-lasting effects are strong candidates for
avoiding MTCT. Therefore, studying immunologic interventions,
such as maternal and infant vaccine regimens, that would reduce
pre- and postnatal HIV transmission remain crucial for protection
against HIV infection.
As the newborn immune system is not fully mature, infants are
sometimes unable to mount an effective immune response against
some pathogens [6,7]. Passive maternal immunization has been
performed to avoid lethal viral and bacterial infections in
newborns [6,8]. However, although maternal Ab represent the
major form of protection against diseases in early life, their
presence can also interfere with active immunizations and infant
immune responses to antigens [9,6].
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There is some evidence that maternal Ab generated after
antigen vaccination negatively influence the vaccine response of
the infant. However, there is strong evidence that DNA-vaccinated
neonates, born from DNA-immunized mothers, can elicit effective
immune responses against herpes simplex virus and malaria
protozoa even in the presence of maternal Ab [10,11]. The use of
DNA vaccines as a strategy to avoid the inhibitory effects of
maternal Ab is based on the fact that the antigen encoded by the
vaccine DNA is not exposed to maternal Ab; antigen presentation
is carried out by the MHC class I and II molecules of cells that
take up DNA [8]. Even if part of the DNA product is secreted and
neutralized by maternal Abs, the remaining product will be
processed and presented as an endogenous antigen.
Our group has previously studied the LAMP/HIV-1-gag
chimeric DNA vaccine in neonate models [12,13]. The lyso-
some-associated membrane protein-1 (LAMP-1) is highly ex-
pressed by all nucleated cells and is found in the MHC class II-
enriched intracellular compartments (MIICs) that are associated
with antigen presentation [14]. Intradermal delivery of the LAMP/
HIV-1-gag DNA vaccine has been shown to (i) elicit enhanced Ab
production, (ii) amplify the anti- Gag CD4+, CD8+ T and B cells
responses, and (iii) prolong immunological memory to Gag
epitopes in adult mouse and monkey experimental models
[14,15,16,12]. Recently, we have shown that mucosal and
intradermal immunization of neonates with the LAMP/HIV-1-
gag (LAMP/gag) construct correlates with strong anti-Gag cellular
and humoral immune responses [12,13].
The rationale for using the LAMP/gag DNA strategy in
maternal immunization was to verify whether subcutaneous
immunization prior to conception could improve the newborn
vaccine response by Ab transfer and allow the generation of
immunological memory on offspring. Moreover, pregnant mice
were also immunized by intravenous route to check whether this
change in the maternal immunization protocol could prime the
offspring in utero and prevent the inhibitory effects of maternal Ab.
In fact, there have been reports showing that intravenous DNA
injection of pregnant mice can prime the fetal immune system
[17,18]. Furthermore, understanding the strong relationship
between fetal and maternal immune systems is essential for
developing strategies of maternal vaccination that avoid neonatal
antigen tolerance.
In the present work, we evaluated the effect of the LAMP/gag
DNA vaccine which was administered to mice either before or
during pregnancy on the neonatal immune response. The
immunization before conception led to a robust transmission of
maternal Ab to offspring, which lasted up to 2 months and did not
interfere with the long-lasting cellular immune response after
neonatal vaccination. Maternal vaccination via the intravenous
route with the chimeric vaccine did not raise Ab and led to in utero
priming of both maternal and fetal immune systems.
Results
LAMP/gag DNA immunization before conception induces
anti-Gag IgG Abs transference through the transplacental
and breastfeeding routes to offspring
Transfer of maternal Ab is essential for protecting newborns
against infectious agents; maternal vaccination can either prime
the neonatal immune system or inhibit the neonatal vaccine
response [9]. To evaluate the mechanisms triggered by maternal
vaccination with LAMP/gag DNA, we first assessed the contribu-
tion of IgG transfer to offspring by the transplacental and
breastfeeding routes. Female BALB/c mice were immunized and
boosted after 20 days by intradermal route with 50 mg LAMP/gag,
gag, or LAMP plasmid DNA. The immunized mice were mated
and maternal serum, amniotic fluid, and milk were collected. Fetal
serum samples were collected by caesarean section, and serum
samples from offspring were collected at different ages.
We have previously demonstrated that immunization with
LAMP/gag DNA preferentially induces production of the IgG1
subclass of Abs in adult and neonate mice [12]. Figure 1A shows
that the LAMP/gag-immunized mothers showed high levels of anti-
Gag IgG1 Abs which is also detected in the amniotic fluid
(Figure 1B), neonatal serum (fetal serum, day 0, Figure 1D), and
milk (Figure 1C). In fact, analysis of neonatal serum showed that
there were significantly higher levels of anti-Gag IgG1 Ab in
newborns from LAMP/gag–immunized mothers than in newborns
from gag–immunized mothers (Figure 1D). Maternal anti-Gag
Figure 1. Transfer of high levels of anti-Gag IgG1 Abs from Lamp/gag DNA-immunized mothers to offspring through transplacental
and breastfeeding routes. Female BALB/c mice were primed and boosted with 50 mg of Lamp (L), gag (G) or Lamp/gag (LG) plasmid DNA and
mated one day after the boost. (A) Maternal serum and (B) amniotic fluid were obtained by caesarean section from full-term pregnant mice. (C)
Breast-milk samples (1:20) were collected on day 5 after delivery and (D) fetal serum from 0-, 30-, 60- and 90-d-o offspring were evaluated by ELISA
using HIV-1 lysates. The results from 4–6 animals per group were expressed as the mean 6 SEM. Schematic diagram of the immunization protocol is
shown. *p#0.05 and ***p,0.001 when compared to gag.
doi:10.1371/journal.pone.0031608.g001
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IgG1 Abs were detected in the serum of offspring from LAMP/gag-
immunized mothers for up to one month after birth. Anti-Gag
IgG2a and IgA Abs were also detected at low levels (Figure S1).
Taken together, these results indicated that maternal immuniza-
tion with LAMP/gag DNA before conception promoted a robust
passive transfer of anti-Gag IgG Abs through the transplacental
and breastfeeding routes both before and after birth.
Effect of maternal DNA immunization on the vaccine
response of offspring
To investigate the effect of maternal immunization with LAMP/
gag DNA on the offspring immune response, adult female mice
were immunized twice with 50 mg DNA at a 20–day interval
according to the prime–boost protocol. Mice were mated one day
after the boost. Seven–and 25–day old (d-o) offspring were
immunized with 5 mg DNA vaccine and evaluated after 30 and 60
days for anti-Gag IgG Ab production. The frequency of IFN-c-
secreting cells stimulated by Gag peptides was evaluated after 60
days. Females and offspring either non-immunized or immunized
with the gag or LAMP DNA vaccine before mating were used as
controls.
Figure 2 shows that maternal immunization with LAMP/
gagDNA promoted the transfer of anti-Gag IgG1 Abs that lasted
up to 30 days. LAMP/gag–immunized neonates from LAMP/gag–
immunized mothers displayed a 70% reduction in anti-Gag IgG1
(Figure 2A) and anti-Gag IgG2a Ab levels (Figure S1) compared to
immunized offspring from non-immune mothers; whereas non-
immunized offspring from gag–immunized mothers had almost
undetectable levels of maternal anti-Gag IgG1 Abs. When
offspring of gag-immunized mothers were immunized, the detected
Ab levels increased to 5% compared to gag-immune offspring from
non-immune mother (Figure 2A). The control group of females
and their respective offspring immunized with pITR-LAMP DNA
did not show any anti-Gag response.
Maternal LAMP/gag–immunization led to a decrease in the
number of IFN-c spot–forming cells (SFCs) against Gag peptides
in LAMP/gag–immunized offspring (Figure 3A). The number of
IFN-c SFCs generated upon stimulation of several peptides,
including those containing MHC class I–and II–restricted
epitopes, decreased in LAMP/gag-immunized offspring from
LAMP/gag-immunized mothers when compared to LAMP/gag-
offspring from non-immunized mothers. The immunodominant
Gag peptides recognized by MHC class I and II molecules of cells
from adult BALB/c mice immunized with LAMP/gag and gag
DNA constructs were peptide fragments from amino acids (aa)181
to aa 227 (MHC class I), aa 241 to aa 271, and aa 281 to aa 311
(MHC class II) as previously reported [15]. Interestingly, maternal
Figure 2. Maternal immunization with the Lamp/gag DNA vaccine decreases anti-Gag IgG1 Ab production in immunized offspring.
Female mice were immunized, and 20 days later, they were boosted with 50 mg Lamp (L), gag (G), or Lamp/gag (LG) plasmid DNA and mated one day
after the boost. Offspring were either non-immunized or immunized with 5 mg of the same vaccine DNA at 7- and 25-d-o. Offspring serum samples
were collected at (A) 30- and (B) 60-d-o (3–8 animals per group). Anti-Gag IgG1 was determined by ELISA using HIV-1 lysates. Bars represent the mean
6 SEM. Schematic diagram of the immunization protocols are shown. *p#0.05 and ***p,0.001 when compared to the respective control offspring
from non-immunized (NI) mothers.
doi:10.1371/journal.pone.0031608.g002
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gag immunization did not interfere with the cellular response
(measured by the number of IFN-c SFCs) of gag-immunized
offspring when compared to the control group (Figure 3B). The
LAMP/gag immunization in turn generated broad epitope
recognition in the neonatal period even after LAMP/gag-maternal
immunization. In fact, when mothers were immunized with the
chimeric vaccine and the offspring with the gag vaccine, the
number of IFN-c SFCs in the offspring decreased (Figure 3B). This
inhibitory effect mediated by LAMP/gag-maternal immunization
was found to be Gag-specific, as there was no decrease in the IFN-
c response to anti-CD3 stimulation. Furthermore, inhibitory
effects after maternal LAMP/gag immunization were also con-
firmed when offspring were immunized with 1 mg LAMP/gag DNA
vaccine (Figure S2).
Due to the inhibitory effect of maternal LAMP/gag immuni-
zation on the offspring vaccine response, we also determined
the level of TGF-b1 in milk. TGF-b is one of the important
factors involved in the generation of T regulatory (T reg) cells,
which contribute to the control of immune responses to
vaccines. TGF-b1 levels were evaluated in milk samples that
were taken from immune or non-immune mothers 7 days
postpartum. Curiously, mothers immunized with either LAMP/
gag or gag DNA showed reduced TGF-b1 levels in their milk 7
days after delivery when compared to non-immunized mothers
(Figure 4A).
We next evaluated whether maternal immunization with LAMP/
gag DNA could interfere with the frequency of T reg cells in the
offspring. We quantified the CD4+CD25+Foxp3+ T cells in spleen
samples of 7-d-o offspring from immune or non-immune mothers
(Figure 4B). Surprisingly, only maternal immunization with LAMP/
gagDNA augmented the percentage of CD4+CD25+Foxp3+T cells
in comparison to the control offspring.
Therefore, maternal immunization with the chimeric LAMP/gag
DNA down-modulated the immune response generated in
immunized offspring, which could be related to the high levels
of anti-Gag maternal Abs present in the offspring as well as to the
generation of CD4+CD25+Foxp3+ T cells by the offspring.
Effect of IgG treatment on LAMP/gag-immunized
offspring
We next evaluated whether maternal anti-Gag IgG Abs could
be involved in the decreased humoral and cellular anti-Gag
immune responses in LAMP/gag-immunized offspring. Purified
IgG from either non-immune or LAMP/gag DNA-immunized
mice was injected into 7–, 13–, and 25–d-o offspring from non-
immunized mothers. Mice were then immunized at 7–and 25–d-o
with 5 mg LAMP/gag DNA.
Injection of IgG from immune mice (IgG-LG) led to a
significant decrease in the anti-Gag IgG Ab response after
offspring immunization (Figure 5A). There was also a decrease
in the cytotoxic T cell response towards the H2-Kd immunodo-
minant epitope in vivo (Figure 5B) when compared to immunized
offspring treated with IgG from non-immune mice (IgG-NI). The
decreased Ab response that occurred when IgG was injected from
immune mice suggested that Ag-specific Abs might inhibit the
LAMP/gag vaccine response in offspring by forming a complex
between Ag and IgG. However, treatment with IgG did not alter
the number of IFN-c SFCs that were generated in response to
MHC class I or class II epitopes (Figure 5C). These results showed
that treatment with IgG from LAMP/gag-vaccinated mice
decreased the humoral and CTL responses in immunized
neonates, whereas other immune cell functions were not affected.
Effect of LAMP/gag DNA maternal immunization on later
T and B cell immune responses on offspring
Although maternal immunization with LAMP/gag DNA inhibits
the humoral and cellular immune responses in offspring, it is
unknown whether maternal immunization affects the late immune
response. The humoral and cellular responses were thus evaluated
Figure 3. Maternal Lamp/gag immunization reduces the IFN-c response of immunized offspring. Offspring from mothers immunized with
Lamp/gag (LG) or gag (G) were immunized with 5 mg of (A) LG or (B) G DNA, respectively. Spleen cells from 35-d-o offspring were cultured with 25
pooled HIV-1 Gag peptides. The figure represents 4–5 assays per group (2–3 animals per group). Bars show the mean 6 SEM. Schematic diagram of
the immunization protocols are shown. *p#0.05 and **p,0.01 when compared with immunized offspring from non-immunized (NI) mothers.
doi:10.1371/journal.pone.0031608.g003
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in 6-month-old offspring from immunized or non-immunized
mother. Figure 6A shows that maternal immunization had no
negative effect on IFN-c producing cells in the LAMP/gag–
immunized offspring for up to 6 months when compared to the
control group (LG offspring – NI mothers). Similarly, as expected,
maternal immunization with gag DNA did not interfere with the
long-lasting IFN-c response in offspring. However, an anti-Gag
IgG Ab response was detected only in 6-month-old offspring
immunized with LAMP/gag DNA following an immunization
boost probably due to the high CD4 T cell augmented response
given by the chimeric vaccine (Figure 6B). After the 6-month LG
DNA boost, the immunized offspring from immune mother
showed similar levels of Anti-Gag IgG levels than the immunized
offspring from non-immune mother (Figure 6B). These results
indicated that although maternal immunization with chimeric
LAMP/gag DNA affected the early response (10-days after the
second boost), it did not impair the late T- and B-cell response (6
months after vaccination).
Intravenous injection of LAMP/gag DNA vaccine during
pregnancy primes the fetal immune system
We also investigated whether it was possible to prime the fetus
immune system with the chimeric DNA Lamp/Gag or conventional
(Gag) DNA vaccine by immunizing pregnant mice. We designed a
second protocol aiming at (i) decreasing the maternal Ab levels,
favoring the priming of the immune system of both mother and
offspring, (ii) priming the offspring during the fetal period and (iii)
avoiding the presence of high maternal Ab levels transferred to the
offspring during their priming with the DNA vaccine. As it is well
known that intravenous (IV) delivery is not an immunogenic route,
and considering the role of the chimeric LAMP/gag DNA on
antigen presentation-cell and CD4+ T cell activation, we
hypothesized that injecting the DNA vaccines intravenously, seven
to five days before delivery, could prime the offspring. We thus
injected a 100 mg single dose of the DNA vaccine during the last 7
to 5 days of pregnancy and assessed the effects in the neonate.
The results showed that one intravenous injection with 100 mg
of LAMP/gag or gag DNA during pregnancy was able to prime
mothers as determined by the induction of IFN-c SFCs that were
generated against the immunodominant MHC class I and II
epitopes and the p24 protein (Fig. 7A). We then compared the
non-immunized offspring and offspring that were immunized with
5 mg DNA vaccine at 7–d-o. Non-immunized offspring of mothers
that received a LAMP/gag DNA injection during pregnancy
produced IFN-c SFCs against p24 (average 69.4 SFCs/106MSCs),
and this number of IFN-c SFCs was significantly higher than that
of non-immunized offspring of G-immunized mothers (2.54 SFC/
106 MSCs). These results strongly suggest that there was in utero
priming following IV injection of the chimeric LAMP/gag DNA
vaccine (Figure 7B). In fact, when the 7-d-o offspring from LAMP/
gag-immunized mothers were then immunized with LAMP/gag, the
amount of IFN-c produced in response to the immunodominant
Figure 4. Effect of maternal DNA immunization on TGF-b1 levels in milk and on the generation of CD4+CD25+ FoxP3+ T cells in
offspring. Female mice were primed and boosted with 50 mg of Lamp/gag (LG), gag (G), or Lamp (L) plasmid DNA and mated one day after the
boost. (A) Breast-milk samples collected 7 days after delivery; (B) percentages of CD4+CD25+Foxp3+ T cells in offspring splenocytes at 7 d-o; (C)
CD4+CD25+FoxP3+ T cells in individual offspring at 7 d-o, non-immunized (NI), or immunized with L, G or LG. The results of 8–12 animals per group
are expressed as the mean 6 SEM. Schematic diagram of the immunization protocol is shown. #p#0.05 and ##p,0.01 when compared with the
non-immunized (NI) group; **p,0.01 when compared with the gag-immunized group.
doi:10.1371/journal.pone.0031608.g004
Figure 5. Transfer of IgG from immune mice decreases CTL numbers and anti-Gag IgG Abs in offspring immunized with LAMP/gag.
Offspring from non-immunized mothers were immunized at 7- and 25-d-o with 5 mg of LAMP/gag (LG) and treated with IgG from non-immune (IgG-
NI) or LG (IgG-LG)-immunized mice at 7-, 13-, and 25-d-o or without IgG treatment (none). (A) Offspring serum samples from 35-d-o mice (n = 6 per
group) were evaluated for anti-Gag IgG Ab levels by ELISA using HIV-1 lysates. (B) In vivo T-cell cytotoxicity was evaluated ten days after LG
immunization. Mice were IV injected with target cells from NI mice stained with low and high concentrations of CFSE. The CFSE-high target cells were
pulsed with a class I immunodominant peptide (AMQMLKETI), and after 18 h, spleen cells were evaluated. (C) IFN-c SFCs from 35-d-o offspring (n = 3
per group) were evaluated after stimulation with Gag MHC class I and II epitopes or recombinant p55 of HIV-1. Bars represent the mean 6 SEM.
Schematic diagram of the immunization protocol is shown. **p#0.01 compared with offspring treated with IgG from NI mice; #p#0.05 compared
with offspring without IgG treatment.
doi:10.1371/journal.pone.0031608.g005
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Figure 6. Maternal LAMP/gag immunization does not interfere with long-lasting IFN-c and B-cell responses in immunized offspring.
Offspring from non-immune (NI) or immune (I) mothers were immunized at 7- and 25-d-o with 5 mg of either Lamp/gag (LG) or gag (G) DNA. Some
neonates groups from I or NI mothers received a 3rd boost at 6-months-old. (A) IFN-c SFCs from 6-month-old offspring after stimulation with MHC H-
2d class I- and II-restricted pools of Gag peptides from HIV-1. The figure represents 4–5 assays per group (2–3 animals per group); *p#0.05 when
compared with immune offspring from NI mothers. (B) Serum from offspring was collected when they were 6 months old (6 animals per group), and
anti-Gag IgG was evaluated by ELISA using HIV-1 lysates. One group received a boost 10 days before analysis. Bars represent the mean 6SEM.
*p#0.05 when compared with immune offspring from NI mothers. Schematic diagram of the immunization protocols are shown **p,0.01 when
compared with gag-immunized offspring.
doi:10.1371/journal.pone.0031608.g006
Figure 7. Intravenous DNA immunization during pregnancy primes the fetal immune system. Pregnant mice were IV immunized
approximately 15–16 days into gestation with 100 mg of Lamp/gag (LG) or gag (G) vaccine DNA. Offspring were either immunized (IM) or not (NI) at 7-
d-o with 5 mg of the DNA vaccine. (A) Mother: IFN-c SFCs from spleen cells of immunized mothers 35 days after delivery and (B) Offspring: IFN-c SFCs
from spleen cells of 35-d-o offspring after stimulation with class I and class II Gag peptides and recombinant p24 of HIV-1. The figure represents 2–3
assays per group (2–3 animals per group). (C) Offspring: Serum samples from 35-d-o NI or IM offspring were evaluated by ELISA using HIV-1 lysates
for anti-Gag IgG concentrations. Bars represent the mean6 SEM. Schematic diagram of the immunization protocol is shown. *p#0.05, **p,0.01, and
*** p,0.001 when compared with G-offspring from a G-mother; +++p,0.001 when compared with NI offspring from a G-immunized mother.
doi:10.1371/journal.pone.0031608.g007
Maternal and Fetal Priming by DNA Immunization
PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e31608
MHC class I and II epitopes and to p24 was markedly enhanced
compared to offspring immunized with Gag (Figure 7B).
Moreover, non-immunized offspring from mothers immunized
at pregnancy had no vertical Ab transfer when mothers were
immunized by IV injection (Figure 7C). Therefore, offspring that
received just one dose of the LAMP/gag vaccine had an increased
Ab response when compared to the gag-immunized offspring
(Figure 7C). Notably, our previous results showed that two vaccine
doses are needed and that an individual dose of the LAMP/gag
vaccine at 7–d-o is not enough to induce anti-Gag Abs [12]. Thus,
the current results suggest that there is a recall response upon in
utero priming in offspring immunized with the LAMP/gag vaccine.
In conclusion, our data showed that intravenous administration
of the DNA vaccine elicited low numbers of IFN-c SFCs and
primed both maternal and fetal immune systems. These results
opened a possibility of priming the fetal immune system in utero,
with the absence of MatAb, although the intensity of cellular and
humoral responses generated by this protocol was lower than that
observed with preconceptional immunization of the mother
followed by neonatal LG immunization. Then, the preconcep-
tional protocol represent the best approach to transfer Ab and to
elicit higher humoral and cellular immune response on immunized
neonate, however if we aim to prime as early as possible the fetus
immune system and to avoid the effect of MatAb on the offspring
vaccine response, we should consider use the intravenous protocol.
Discussion
Maternal immunization with LAMP/gag DNA before concep-
tion or during pregnancy was assessed to evaluate the neonatal
immune response to the DNA vaccine and the possibility for in
utero priming, respectively. We have previously shown that
administration of the chimeric LAMP/gag DNA vaccine at the
neonatal stage is highly immunogenic, as it elicits high levels of
anti-Gag Abs and elevated cellular immune responses towards the
HIV–gag antigen when compared to immunization with a DNA
construct expressing the Gag antigen only [12,13]. However, it
was unknown whether maternal immunization with the chimeric
LAMP/gag DNA vaccine could affect the offspring response to the
vaccine.
Our results indicated that maternal immunization with the
chimeric DNA vaccine by subcutaneous injection before concep-
tion promoted passive Ab transfer that caused a transitory
inhibition of the offspring response to the construct. Nonetheless,
this inhibition did not impair the long-lasting B- and T-cell
responses in the offspring. Moreover, the high levels of Ab that
were elicited when maternal immunization occurred prior to
conception were circumvented when an individual intravenous
dose of the LAMP/gag DNA was administered during pregnancy.
The intravenous route of immunization was less immunogenic
than the intradermal route, but it was still able to prime both
mother and offspring.
Immunization with the LAMP/gag DNA vaccine before
conception led to the transfer of high levels of anti-Gag IgG1
Abs through the placental/amniotic and breastfeeding routes.
IgG1 Abs are the major subclass of Abs produced by adult and
neonate BALB/c mice immunized with LAMP/gag DNA [12], and
IgG1 Abs were the main Ab subclass that were transmitted to the
offspring. Maternal Ab levels lasted up to 60 days in the offspring
circulation, indicating that breast milk was an important source of
IgG, as weaning takes place at approximately 25 days after birth,
and the half-life of IgG is 30 days. The FcRn–IgG Fc receptor,
which is expressed in the small intestine of suckling mice and rats,
is the main molecule involved in IgG uptake from ingested
maternal milk [19]. In mice, the yolk sac endoderm constitutively
takes up IgG into the fetal circulation [20]. The gag DNA vaccine
induced low Ab responses, and consequently, low levels of Ab were
transferred to the offspring.
Maternal immunization with LAMP/gag DNA decreased the
anti-Gag IgG1 and IgG2a Ab levels and the number of anti-Gag
IFN-c SFCs in LAMP/gag–immunized offspring when compared
to the LAMP/gag–immunized offspring from non-immunized the
negative impact of LAMP/gag maternal immunization on the 35-d-
o offspring response to the immunization, it did not hinder the
broad T-cell recognition of Gag epitopes in the neonates. It is not
clear whether the decreased number in IFN-c SFC could interfere
in the quality of the total anti-Gag immune response; the decrease
in the IFN-c SFC numbers against the class I and II MHC
epitopes _ represented by the immunodominant epitopes and not
by all of the recognizable epitopes _ by ELISPOT assay do not
predict the whole functionality of these Ag-specific T cells. These
results should be considered when reviewing how the assays were
performed, the ELISPOT assays for determination of IFN-c SFCs
represent an in vitro recall response to the stimulating peptides,
whereas IgG Ab levels and the cytotoxic assay use in vivo or ex vivo
parameters as a readout.
Nevertheless, six months after neonatal immunization with
LAMP/gag DNA, no inhibitory effect was detected on the anti-Gag
IFN-c response to class I or II Gag peptides. This result
demonstrates that despite the active suppression in early responses,
the generation of T-cell memory responses was intact. However, a
boost with LAMP/gag DNA was necessary to elicit an anti-Gag Ab
response in six-month-old offspring. As expected, a B-cell late
response was generated only with the LAMP/gag immunization
and after the 3rd boost, probably due to the higher CD4 T cell
activation and T-B cell cooperation.
The presence of maternal anti-Gag Abs in neonates is likely the
main inhibitory mechanism for immunizing offspring, as these Ab
can form immune complexes with the Gag protein when it is
transduced upon LAMP/gag DNA immunization. In fact, when
neonates were injected with purified IgG from immune mice in
conjunction with the LAMP/gag DNA immunization, they showed
an inhibition of the humoral and in vivo cytotoxic T cell responses
to the H-2dclass I immunodominant peptide. Interestingly, the
IgG injections did not interfere with the IFN-c response to the Gag
peptides or the p24 protein as compared to the LAMP/gag-
immunized mice that received IgG from non-immune mice. The
in vivo cytotoxicity of CD8+ T cells is not dependent on IFN-c as
recently shown in a murine model of prime-boosting using DNA
and recombinant adenoviruses against Chagas disease; here,
protection against the disease was reduced in IFN-c2/2 mice
even in the presence of specific CTLs [21]. However, it is still
possible that other regulatory mechanisms independent of
maternal Abs contribute to the attenuation of the offspring
immune response to the vaccine.
Several mechanisms by which maternal factors influence the
immune response in offspring have been described and suggested,
including the following: (i) formation of immune complexes with
the antigen, which impairs neonatal priming [8]; (ii) anti-idiotypic
maternal Ab interaction with immature B and T cells in primary
lymphoid organs, or negative or positive modulation of plasma
and T cell differentiation [22]; (iii) maternal transfer of cytokines
that are able to control cell activation by downregulating the
expression of co-stimulatory and activation molecules on dendritic
cells and T and B lymphocytes [23,6]; (iv) interaction of maternal
Ab immune complexes with the B-cell inhibitory receptors that
mediate negative regulation of B-cell function [23]; and (v)
generation of T regulatory cells [6]. Our group has been exploiting
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the capacity of maternal immunization with allergens to
dowmodulate the newborn allergic response [24,23,25,26]. Our
findings have shown that allergy prevention in offspring whose
mothers were immunized is mainly due to the formation of
immunocomplexes with allergens and maternal Abs as well as the
upregulation of the inhibitory FccRIIb receptor in offspring B cells
[25,23].
Notably, one effect of the maternal immunization with LAMP/
gag was the induction of a high percentage of CD4+
CD25+FoxP3+ T cells in 7-d-o neonates despite the reduction
of TGF-b1 levels in milk. TGF-b1 is essential for the generation of
induced T reg cells [27]; however, it is not clear why only offspring
from LAMP/gag-immunized mothers showed increased percent-
ages of CD4+CD25+FoxP3+ T cells in the spleen. It is possible
that other factors are involved in the modulation of the offspring
immune response promoted by the LAMP/gag immunization. In
fact, it has been shown that T reg cells regulate inflammation
during infections, but a high number of T reg cells can suppress
the antiviral response [28]. Furthermore, the cells with phenotype
of T reg generated after maternal LAMP/gag DNA vaccination
could function in controlling offspring immune activation after
immunization.
There is evidence that to achieve an efficient immune response
in offspring, maternal Abs should be directed against epitopes
other than neonatal epitopes, thereby avoiding inhibition the
offspring response to vaccination [29]. In this case, we should
consider the use of different DNA constructs in maternal and
offspring immunizations and find a vaccination protocol that is
immunogenic in the newborn and can overcome the inhibition
caused by maternal Abs. Considering that the chimeric LAMP/gag
DNA raised Ab titers by 50 to 100-fold and that it was more
immunogenic during the neonatal period, we evaluated the effects
of IV immunization of pregnant mice with LAMP/gag DNA on the
immunogenicity of LAMP/gag-vaccinated offspring. Maternal
immunization was performed close to birth to avoid high levels
of Ab transfer to offspring. Our results showed that IV
immunization with LAMP/gag DNA five to seven days before
delivery generated T and B cell responses in mothers and
offspring, confirming that is possible to use a DNA vaccine to
prime both the fetus in utero and the immune system of the mother.
Moreover, this approach confirmed that the LAMP/gag DNA
construct was able to elicit multiple immune responses compared
to conventional gag DNA immunization, particularly T-cell
activation. Despite a lower magnitude of the immune response
observed with the intravenous DNA immunization, just one dose
of the chimeric vaccine by intravenous injection in the last few
days of pregnancy was able to prime both maternal and fetal
immune systems. The transfer of plasmid to the fetus through the
placenta and amniotic fluids has been a concern, as it may cause
tolerance of the offspring immune system towards the plasmid-
encoded antigen. The current study and those by others have
confirmed that this is not the case [30,17,18,31]. Moreover, use of
LAMP/gag DNA vaccination during pregnancy could be an
advantage by subjecting newborns to fewer doses but enough
doses to generate an immune response.
Together, our data showed that the chimeric LAMP/gag DNA
construct, which targets the Gag antigen to MIIC compartments,
more efficiently induced T and B cell responses in mice at various
stages in life, compared to the conventional DNA construct
expressing gag only. Even in the presence of MatAb, the LAMP/gag
DNA, administered in the neonatal period, elicited broad T cell
responses and considerable B cell responses. Furthermore,
preconceptional immunization with LAMP/gag, inducing MIP-1a
secretion (data not show) – natural blocker of infection - and
increasing T reg cell numbers in the offspring, could be protective
against HIV-1 infection by inhibiting viral entry into target cells
and reducing CD4+ T cell activation. Moreover, giving the
LAMP/gag DNA vaccine during pregnancy primed both maternal
and fetal immune systems. Therefore LAMP-1 with other HIV-1
antigens should be considered in the development of a protective
vaccine for the maternal/fetal and newborn periods.
Materials and Methods
Mouse immunization
8- to 10-week-old BALB/c mice were purchased from CEMIB
(UNICAMP, Campinas, Sa˜o Paulo, Brazil) and bred in our
pathogen-free animal facility. The Sa˜o Paulo University Institu-
tional Animal Care and Use Committee approved the present
study.
Plasmids
A eukaryotic expression plasmid with the fragment of the HIV-1
HXB2 p55gag gene, nucleotides 1-1503 (GenBank accession
number KO3455), was inserted into the mammalian expression
vector, pITR [32], which contains a cytomegalovirus promoter
and the ITR sequences from adeno-associated virus flanking the
expression elements. The mouse LAMP-1 gene (GenBank J03881)
was cloned into this vector, resulting in the chimeric LAMP/gag
plasmid with the p55gag sequence placed between the LAMP-1
luminal domain and the transmembrane/cytoplasmic tail as
previously described [14]. Plasmid DNA was produced by
transforming DH5a Escherichia coli (Invitrogen, Carlsbad, CA),
and plasmids were purified using an endotoxin-free column
(Qiagen Inc., Valencia, CA).
Immunization protocols
Maternal immunization before conception. Female
BALB/c mice were immunized (homologous prime-boost) twice
by the intradermal route (ID immunized) at a 20-day interval with
50 mg of one of the following plasmid DNAs: pITR-LAMP/gag
(LAMP/gag-LG), pITR-gag (gag-G), or pITR-Lamp (Lamp-L). Mice
were mated after the boost. Offspring were immunized with the
same vaccine as their mothers.
Maternal immunization during pregnancy. Pregnant
BALB/c mice received 100 mg of the LAMP/gag or gag DNA
vaccine by intravenous (IV) injection 7-5 days before delivery.
Neonatal immunization. 7- and 25-day-old (d-o) neonates
were ID immunized with 1 or 5 mg of LAMP/gag (LG), gag, or Lamp
DNA and subjected to analysis at different ages.
Passive transfer of IgG from immunized mice. Neonate
mice received intraperitoneal (IP) injections at 7-, 13-, and 25-d-o
with 100 mg of purified IgG from immune (LG) and non-immune
(NI) mice, similar to the DNA immunization protocol. IgG was
purified using the Melon Gel IgG Spin Purification kit according
to the manufacturer’s instructions (Pierce, Rockford, IL) and
stored at 270uC until use. IgG measurements were performed by
enzyme- linked immunosorbent assay (ELISA).
Collection of amniotic fluid, fetal and maternal sera and
milk
To evaluate vertical transmission of Ab, amniotic fluid and fetal
serum samples were obtained by caesarean section of full-term
pregnant mice (21 days) and stored at 270uC until use. Mothers
were bled at the time of parturition and on day 20 postpartum.
Milk samples were obtained from the stomachs of 5- or 7-d-o
newborns as previously described [33].
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Ab response
Anti-Gag IgG Ab levels were assessed by ELISA) as previously
described [12]. Briefly, 96-well microplates (Greiner, German)
were coated with 5 mg/mL HIVIIIB lysate (ABI, Rockville, MD)
and incubated overnight at 4uC. After blocking with PBS-0.5%
gelatin for 1 h at 37uC, the plates were washed three times with
PBS and incubated with serially diluted sample for 2 h at 37uC.
After washing with PBS-0.5% Tween, the plates were incubated
with biotinylated Ab anti-c1 (Southern Biotech, Birmingham,
Alabama, USA) for 1 h at 37uC followed by the addition of
streptavidin peroxidase (Sigma, St. Louis, MO, USA). The
reaction was developed with tetramethyl benzidine (Calbiochem
Corporation, San Diego, CA, USA), and the absorbance was read
at 450 nm in an ELISA microplate reader (Bio-Rad, USA).
Isolation of mononuclear spleen cells
Spleens were obtained aseptically and mashed through cell
strainers (BD-Biosciences, San Diego, CA, USA), and mononu-
clear spleen cells (MSCs) were isolated after centrifugation in
Ficoll-Hypaque solution (Sigma, St. Louis, MO, USA). After two
washes, the cell pellet was diluted in RPMI 1640 containing 10%
fetal calf serum (FCS, HyClone III, Logan, UT, USA). Viability
was greater than 95%.
Gag-specific IFN-c ELISPOT assay
Enumeration of IFN-c–producing splenic T cells was performed
by ELISPOT assay (BD-Biosciences) as previously described [12].
Briefly, 96-well microplates with polyvinylidene fluoride mem-
brane support (Millipore, Bedford, MA, USA) were incubated with
anti-IFN-c for 18 h at 4uC, washed and blocked with RPMI
containing 10% FCS for 2 h at room temperature. Cells (56105
cells/well) were plated in the presence of medium alone, hamster
monoclonal anti-mouse CD3 (1 mg/mL,BD-Biosciences),10 mg/
mL HIV-1 Gag epitope restricted to H-2d MHC class I
AMQMLKETINEEAAE197–211,10 mg/mL HIV-1 Gag epitope
restricted to H-2d MHC class II VDRFYKTLRAEQASQ297–308
(NIH AIDS Research and Reference Reagent Program), 2 mg/mL
p24Gag from HIV-1 (kindly provided by Prof. Luis Carlos
Ferreira, Institute of Biomedical Sciences, University of Sa˜o
Paulo), or 10 mg/mL of 25 pools containing five HIV-Gag
peptides (15-mers of the HIV-1 HXB2gag peptide), totaling 123
peptides, for 18 h at 37uC in 5% CO2. The plates were washed,
incubated with biotinylated anti-IFN-c followed by incubation
with avidin-peroxidase, and developed with the 3-amino-9-
ethylcarbazole substrate (Calbiochem). Spots were quantified with
an ImmunoSpot Imager using the ImmunoSpot 3.2 software
(CTL ImmunoSpotH S4 Analyzer, C.T.L., Cleveland, OH, USA).
The reaction was considered positive when the number of spot-
forming cells (SFCs) was equal to or higher than 10 SFC/106 cells.
All results were expressed as the mean number of SFCs per 106
MSCs.
In vivo analysis of CTL activity
Ten days after immunization with 5 mg of the DNA vaccine,
offspring received target cells as previously described with
modifications [12]. Briefly, MSCs from non-immunized (NI)
BALB/c mice were used as target cells, and these cells were
stained with high (10 mM) or low (1 mM) concentrations of
carboxyfluorescein succinimidyl ester (CFSE, Molecular Probes,
USA) in RPMI medium and incubated for 30 minutes at 37uC in
the dark. The population stained with high concentrations of
CFSE was pulsed with 2 mg of the class I peptide, AMQMLK-
ETI197–205, for one hour at 37uC. Target cells with low and high
concentrations of CFSE were washed and mixed at a 1:1 ratio in
PBS. Approximately 36107 cells in 200 mL of PBS were IV
injected into immunized mice (IM). Splenocytes from IM were
collected after 18 hours, and transferred target cells were
evaluated by flow cytometry based on high and low intensities
of CFSE staining. The lysis percentage was determined by
the following calculation: percentage of specific lysis = 1002
{[(% CFSEhigh cells IM/% CFSElow cells IM)/(% CFSEhigh cells
NI/% CFSElow cells NI)]6100}.
Immunophenotyping of CD4+CD25+FoxP3+ T cells
MSCs were incubated with PerCP-conjugated anti-CD4 (BD-
Biosciences), PE-conjugated anti-CD25 or isotype control for
30 min at 4uC. After washing, the cells were fixed with 4%
paraformaldehyde for 10 min at 4uC. Cells were then incubated
with PBS–0.5% saponin (Sigma) and FITC-conjugated anti-FoxP3
(eBioscience, San Diego, CA). After washing, the cells were
analyzed by flow cytometry (BD FACSCalibur, Cell Quest PRO).
A minimum of 250,000 events was collected from the lymphocyte
gate.
Measurement of TGF-b1 in milk samples
An ELISA for TGF-b1 (Promega, Madison, USA) was
performed to measure concentrations in milk samples according
to the manufacturer’s recommendations. The detection limit of
TGF-b1 was 32 pg/mL.
Statistics
Values for all measurements are expressed as the mean6 SEM.
Comparison between two groups was performed by the Mann-
Whitney test; differences were considered significant when the p
value was ,0.05. Three or more groups were analyzed using the
Kruskall-Wallis test with Dunn’s post-test. The data were analyzed
using the GraphPad Prism 3.0 software package (GraphPad, San
Diego, California, USA).
Supporting Information
Figure S1 Transfer of anti-Gag Ab to offspring. Female
BALB/c mice were primed and boosted with 50 mg of Lamp (L),
gag (G), or Lamp/gag (LG) DNA and mated one day after the boost.
(A) Serum samples from 0- (fetal), 30-, 60- and 90-d-o offspring
were obtained by caesarean section from full-term pregnant mice,
and offspring were bled monthly; (B) breast milk samples (1:20)
were obtained 5 days after delivery, and anti-Gag Ab levels were
determined by ELISA using HIV-1 lysates. The results of 4–6
animals per group were expressed as the mean 6 SEM. *p#0.05
and **p,0.01 when compared to Lamp.
(TIF)
Figure S2 Maternal Lamp/gag immunization reduces
the IFN-c response in immunized offspring. Offspring
from mothers immunized with either gag (G) or Lamp/gag (LG)
were immunized with 1 mg of (A) LG or (B) G DNA. Spleen cells
from 35-d-o offspring were cultured with 25 pooled of HIV-1Gag
peptides. The figure represents 4–5 assays per group (2–3 animals
per group). Bars represent the mean 6 SEM. *p#0.05 and
**p,0.01 when compared with immune offspring from non-
immunized (NI) mothers.
(TIF)
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